Rocket's PRV goes for $180M; Oruka targets $500M offering
Rocket sells PRV for $180M: The New Jersey gene therapy maker sold the rare pediatric disease priority review voucher to an undisclosed buyer. Rocket Pharmaceuticals got the PRV after securing FDA ...
Read the full article on the original site.
Read Full Article